Cargando…
The Potential Revolution of Cancer Treatment with CRISPR Technology
SIMPLE SUMMARY: Clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein (Cas) 9 is a novel technology utilized to modify target genes. Here, we highlight how this versatile technique can be applied to the development of novel therapies for oncology in the preclin...
Autores principales: | Stefanoudakis, Dimitrios, Kathuria-Prakash, Nikhita, Sun, Alexander W., Abel, Melissa, Drolen, Claire E., Ashbaugh, Camille, Zhang, Shiliang, Hui, Gavin, Tabatabaei, Yeganeh A., Zektser, Yuliya, Lopez, Lidia P., Pantuck, Allan, Drakaki, Alexandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046289/ https://www.ncbi.nlm.nih.gov/pubmed/36980699 http://dx.doi.org/10.3390/cancers15061813 |
Ejemplares similares
-
Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in the Management of Advanced and Metastatic Urothelial Carcinoma
por: Hui, Gavin, et al.
Publicado: (2023) -
Immunotherapy and Metastatic Renal Cell Carcinoma: A Review of New Treatment Approaches
por: Kathuria-Prakash, Nikhita, et al.
Publicado: (2021) -
Treatment Equity in the Immunotherapy Era: Options for Patients with Both Autoimmune Disease and GU Cancers
por: Hui, Gavin, et al.
Publicado: (2022) -
Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
por: Faiena, Izak, et al.
Publicado: (2018) -
The CRISPR revolution in fungal biology and biotechnology, and beyond
por: Idnurm, Alexander, et al.
Publicado: (2018)